EVO News and Press, Evotec SE From 08/10/22

Evotec ( NASDAQ: EVO ) said its Seattle-based unit Just - Evotec Biologics expanded a multi-year partnership with Alpine Immune Sciences ( NASDAQ: ALPN ) to develop a commercial process for ALPN-303. Evotec said ALPN-303 is being developed t...

JUST - EVOTEC BIOLOGICS WILL APPLY ITS FULLY INTEGRATED TECHNOLOGY PLATFORM TO DEVELOP AN OPTIMISED COMMERCIAL PROCESS FOR ALPN-303, A DUAL BAFF/APRIL INHIBITOR FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND OTHER AUTOIMMUNE AND INFLAMMATORY DISEASES HAMBURG, GERMANY & SEATTLE, WA / ACCESSWI...

HAMBURG, GERMANY / ACCESSWIRE / August 4, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first half-year 2022 on Thursday, 11 August 2022. The Company is going to hold a conference call to discuss th...

Boehringer Ingelheim, Evotec ( NASDAQ: EVO ) ( OTCPK:EVOTF ) and bioMérieux formed a joint venture called Aurobac Therapeutics SAS to develop antimicrobials and diagnostics to fight Antimicrobial Resistance (AMR). Aurobac, which will develop a new precision me...

ALL AGENDA ITEMS ADOPTED WITH THE REQUIRED MAJORITY CAMILLA MACAPILI LANGUILLE ELECTED AS NEW MEMBER OF THE SUPERVISORY BOARD; KASIM KUTAY RESIGNS FROM SUPERVISORY BOARD AUTHORISED CAPITAL 2022 RESOLVED REVISED REMUNERATION SYSTEM FOR MANAGEMENT BOARD APPROVED HAMBURG, G...

STRATEGIC PARTNERSHIP LEVERAGES EVOTEC'S PROPRIETARY PLATFORM CAPABILITIES IN THE FIELD OF PROTEIN HOMEOSTASIS HAMBURG, GERMANY / ACCESSWIRE / June 14, 2022 / Evotec SE (FRA:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO) announced today that the Company has entered a drug discovery ...

CELLS PLATFORM INTEGRATES INNOVATIVE OFF-THE-SHELF IPSC CELL THERAPY DISCOVERY WITH DEVELOPMENT AND MANUFACTURING HAMBURG, GERMANY / ACCESSWIRE / May 30, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced the signing of a defini...

THE MULTI-TARGET RESEARCH AND DEVELOPMENT PARTNERSHIP WILL FOCUS ON SEVERE SKIN DISEASES, INCLUDING IMMUNE-MEDIATED INFLAMMATORY CONDITIONS SUCH AS ATOPIC DERMATITIS AND NON-MELANOMA SKIN CANCER SUCH AS BASAL CELL CARCINOMA THE COLLABORATION LEVERAGES EVOTEC'S DATA-DRIVEN EVO IR&a...

Partnership Leverages Sernova’s Proprietary Cell Pouch System™ with Evotec’s iPSC-Based Insulin-Producing Beta Cells Partners to Develop and Commercialize an Off-The-Shelf Cell Replacement Therapy for Treatment of Patients with Insulin-Dependent Diabetes ...

Germany-based Evotec (NASDAQ:EVO) (OTCPK:EVOTF) and Canada's Sernova (OTCQB:SEOVF) are collaborating to develop a therapy for diabetes. The companies plan to develop an implantable iPSC-based beta cell replacement therapy to treat insulin-dependent diabetes, including type 1 and 2. Under...